» Articles » PMID: 36722512

Therapeutics in Paediatric Genetic Diseases: Current and Future Landscape

Overview
Journal Singapore Med J
Specialty General Medicine
Date 2023 Feb 1
PMID 36722512
Authors
Affiliations
Soon will be listed here.
Abstract

There are more than 7,000 paediatric genetic diseases (PGDs) but less than 5% have treatment options. Treatment strategies targeting different levels of the biological process of the disease have led to optimal health outcomes in a subset of patients with PGDs, where treatment is available. In the past 3 decades, there has been rapid advancement in the development of novel therapies, including gene therapy, for many PGDs. The therapeutic success of treatment relies heavily on knowledge of the genetic basis and the disease mechanism. Specifically, gene therapy has been shown to be effective in various clinical trials, and indeed, these trials have led to regulatory approvals, paving the way for gene therapies for other types of PGDs. In this review, we provide an overview of the treatment strategies and focus on some of the recent advancements in therapeutics for PGDs.

Citing Articles

: reflecting on 2023.

Ang T, Choolani M, Poh K Singapore Med J. 2023; 64(12):713.

PMID: 38047329 PMC: 10775291. DOI: 10.4103/singaporemedj.SMJ-2023-267.


Genetics and genomics: A frontier for clinicians.

Chan H, Loong S, Foo R Singapore Med J. 2023; 64(1):2-3.

PMID: 36722510 PMC: 9979795. DOI: 10.4103/SINGAPOREMEDJ.SMJ-2021-444.

References
1.
Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L . Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020; 91(11):1166-1174. DOI: 10.1136/jnnp-2020-323822. View

2.
Baranello G, Darras B, Day J, Deconinck N, Klein A, Masson R . Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med. 2021; 384(10):915-923. DOI: 10.1056/NEJMoa2009965. View

3.
Levy H, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz F . Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007; 370(9586):504-10. DOI: 10.1016/S0140-6736(07)61234-3. View

4.
Schlander M, Beck M . Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin. 2009; 25(5):1285-93. DOI: 10.1185/03007990902892633. View

5.
Butchbach M . Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci. 2016; 3:7. PMC: 4785180. DOI: 10.3389/fmolb.2016.00007. View